Key result
Propofol target-controlled infusion using the PGIMER model was comparable to the Marsh model in maintaining target plasma concentrations during open heart surgery (MDPE -5.0% vs -6.4%).
Why the study?
Does propofol target-controlled infusion using the PGIMER model perform non-inferiorly to the Marsh model in maintaining target plasma concentrations in adult patients undergoing open heart surgery?
RCT (n=23)
Randomized
Does propofol target-controlled infusion using the PGIMER model perform non-inferiorly to the Marsh model in maintaining target plasma concentrations in adult patients undergoing open heart surgery?
Absolute Event Rate: -5% vs -6.4%
The PGIMER pharmacokinetic model for propofol target-controlled infusion performs comparably to the Marsh model in patients undergoing open heart surgery.
Supports PGIMER model as alternative for propofol TCI in cardiac surgery; extends pharmacokinetic validation in surgical populations.
UNLABELLED: We compared the performance of a propofol target-controlled infusion (TCI) using Marsh versus PGIMER models in patients undergoing open heart surgery, in terms of measured plasma levels of propofol and objective pharmacodynamic effect. METHODS: Twenty-three, ASA II/III adult patients aged 18-65 years and scheduled for elective open heart surgery received Marsh or PGIMER (Postgraduate Institute of Medical Education and Research) pharmacokinetic models of TCI for the induction and maintenance of anaesthesia with propofol in a randomized, active-controlled, non-inferiority trial. The plasma levels of propofol were measured at specified time points before, during and after bypass. RESULTS: The performances of both the models were similar, as determined by the error (%) in maintaining the target plasma concentrations: MDPE of -5.0 (-12.0, 5.0) in the PGIMER group vs -6.4 (-7.7 to 0.5) in the Marsh group and MDAPE of 9.1 (5, 15) in the PGIMER group vs 8 (6.7, 10.1) in the Marsh group. These values indicate that both models over-predicted the plasma propofol concentration. CONCLUSIONS: The new pharmacokinetic model based on data from Indian patients is comparable in performance to the commercially available Marsh pharmacokinetic model.
No takes yet. Share an insight, caveat, or question.
Mathew et al. (2015) conducted an RCT in Open heart surgery (n=23). Propofol target-controlled infusion (TCI) using PGIMER model vs. Marsh model was evaluated on Error (%) in maintaining the target plasma concentrations (Median prediction error [MDPE]). Propofol target-controlled infusion using the PGIMER model was comparable to the Marsh model in maintaining target plasma concentrations during open heart surgery (MDPE -5.0% vs -6.4%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: